Skip to main content
  • Common coronavirus infections don’t generate effective antibodies against SARS-CoV-2

    Although SARS-CoV-2 has taken the world by storm, it’s not the only coronavirus that can infect humans. But unlike SARS-CoV-2, common human coronaviruses (HCoVs) generally cause only mild disease. Now, researchers reporting in ACS Infectious Diseases have shown that infections with two different HCoVs don’t generate antibodies that effectively cross-react with SARS-CoV-2. So, prior infection with HCoVs is unlikely to protect against COVID-19 or worsen a SARS-CoV-2 infection through antibody-dependent enhancement (ADE), the researchers say.

  • Ph.D, M.Pharm, M.Sc Job for CRISPR Based Covid-19 diagnostics at Patanjali Pharma Pvt Ltd

    Patanjali Pharma Pvt Ltd. has been performing research of national importance in collaboration with different national and international organizations. It has been working on major thrust areas like diagnostics and therapeutics for COVID-19, Drug Resistant Tuberculosis, Malnutrition and other infectious disorders. The startup is dedicated to provide an excellent environment for speedy research on Covid-19, Tuberculosis, malnutrition and other areas. We are looking suitable candidates for various intern  positions.

  • T Cell Response Not Critical for Immune Memory to SARS-CoV-2 or Recovery from COVID-19

    New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections. T cell depletion does not induce severe disease, and T cells do not account for the natural resistance of rhesus macaques to severe COVID-19. Furthermore, strongly T cell-depleted macaques still develop potent memory responses to a second infection. 

  • Regdanvimab demonstrates strong neutralising activity against Delta variant of COVID-19

    Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab, CT-P59 has a strong neutralising effect against the rapidly spreading Delta variant, B.1.617.2, first identified in India.

    According to the World Health Organization, WHO, the Delta variant has been reported in 96 countries becoming the most common variant.1

  • Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19

    Cipla Limited, Dr. Reddy’s Laboratories Ltd, Emcure Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited and Torrent Pharmaceuticals Limited announced that the five companies will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India.

  • Pharmacy Recruitment under Health and Family Welfare Department, MCC

    Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states.

  • Strides partnered with Ennaid for AI based COVID-19 medicine

    Strides Pharma Science Limited announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

Subscribe to COVID‐19

Search this website